ADVERTISEMENT
From Italy to Greece and Portugal, off-label use of GLP-1 drugs like Ozempic and Mounjaro for weight loss is creating a booming private market—and a brewing public health dilemma.
In a matter of just a few years, Europe has…
Continue Reading